Literature DB >> 10068602

A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease.

R Porwancher1.   

Abstract

A two-step approach for diagnosis of Lyme disease, consisting of an initial EIA followed by a confirmatory Western immunoblot, has been advised by the Centers for Disease Control and Prevention (CDC). However, these criteria do not examine the influence of the prior probability of Lyme disease in a given patient on the predictive value of the tests. By using Bayesian analysis, a mathematical algorithm is proposed that computes the probability that a given patient's Western blot result represents Lyme disease. Assuming prior probabilities of early Lyme disease of 1%-10%, the current CDC minimum criteria for IgM immunoblot interpretation yield posttest probabilities of 4%-32%. The value of the two-step approach for diagnosis of early Lyme disease may be limited in populations at lower risk of disease or when patients present with atypical signs and symptoms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068602     DOI: 10.1086/314651

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Improving the specificity of recombinant immunoassays for lyme disease.

Authors:  Richard Porwancher
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

2.  A European multicenter study of immunoblotting in serodiagnosis of lyme borreliosis.

Authors:  J Robertson; E Guy; N Andrews; B Wilske; P Anda; M Granström; U Hauser; Y Moosmann; V Sambri; J Schellekens; G Stanek; J Gray
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics.

Authors:  Richard B Porwancher; C Greg Hagerty; Jianqing Fan; Lisa Landsberg; Barbara J B Johnson; Mark Kopnitsky; Allen C Steere; Karen Kulas; Susan J Wong
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

4.  C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Authors:  Dean A Jobe; Steven D Lovrich; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

5.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

6.  Prospective study of serologic tests for lyme disease.

Authors:  Allen C Steere; Gail McHugh; Nitin Damle; Vijay K Sikand
Journal:  Clin Infect Dis       Date:  2008-07-15       Impact factor: 9.079

7.  Lyme disease testing by large commercial laboratories in the United States.

Authors:  Alison F Hinckley; Neeta P Connally; James I Meek; Barbara J Johnson; Melissa M Kemperman; Katherine A Feldman; Jennifer L White; Paul S Mead
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

8.  Outer surface protein C peptide derived from Borrelia burgdorferi sensu stricto as a target for serodiagnosis of early lyme disease.

Authors:  Paul M Arnaboldi; Rudra Seedarnee; Mariya Sambir; Steven M Callister; Josephine A Imparato; Raymond J Dattwyler
Journal:  Clin Vaccine Immunol       Date:  2013-01-30

9.  Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1.

Authors:  Richard I Horowitz; Phyllis R Freeman
Journal:  Int J Gen Med       Date:  2019-02-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.